was recommended; however, the family declined treatment.
Wound management, tetanus prevention and passive immunity administration Clean, minor All other wounds wounds including including Vaccination status infection-related ones infection-related ones Unknown or <3 doses TT and recommend TT and recommend of TT-containing catch-up vaccination catch-up vaccination: vaccine TIG <5 years 75 IU, 5-10 years 125 IU, >10 years 250 IU [greater than or No indication No indication equal to] 3 doses of TT-containing vaccine and <5 years since last dose [greater than or TT recommended TT recommended equal to] 3 doses of TT-containing vaccine and >5 years since last dose TT = tetanus toxoid; TIG = tetanus immunoglobulin
are actively transported through the placenta from an immunized mother to her foetus, providing passive protection against Tetanus during Neonatal period & following month or two of life.
is indicated when patients who have been taking rituximab within the previous 6 months develop a contaminated wound.
Dr David Salisbury, director of immunisation policy at the Department of Health, has written to hospitals advising them on how to deal with shortages of tetanus immunoglobulin
Table 2 lists indications for tetanus toxoid and tetanus immunoglobulin
Patients received intramuscular human tetanus immunoglobulin
and tetanus toxoid on admission.
In the United Kingdom, 5 doses of tetanus toxoid--containing vaccine at appropriate intervals are considered to provide lifelong protection, as long as tetanus-prone wounds are treated with tetanus immunoglobulin